A phase II study of bryostatin I in metastatic malignant melanoma
1998

Bryostatin I in Metastatic Malignant Melanoma

Sample size: 16 publication Evidence: low

Author Information

Author(s): DJ Propper, V Macaulay, KJ O'Byrne, JP Braybrooke, SM Wilner, TS Ganesan, DC Talbot, AL Harris

Primary Institution: ICRF Medical Oncology Unit, Churchill Hospital, Oxford, UK

Hypothesis

Is bryostatin I effective in treating metastatic malignant melanoma in patients previously treated with chemotherapy?

Conclusion

Single-agent bryostatin appears ineffective in the treatment of metastatic melanoma in patients previously treated with chemotherapy.

Supporting Evidence

  • Of 15 evaluable patients, 14 developed progressive disease.
  • One patient achieved stable disease for 9 months after treatment.
  • The median survival from commencement of bryostatin was 134 days.

Takeaway

The study tested a drug called bryostatin on patients with skin cancer, but it didn't help most of them get better.

Methodology

Patients received bryostatin 25 µg/m² weekly for three courses followed by a rest week, and their responses were evaluated.

Limitations

All patients had previously received chemotherapy, which may have affected the results.

Participant Demographics

16 patients (8 men, 8 women) aged 35-76 years, all with prior chemotherapy.

Statistical Information

Confidence Interval

95% CI = 67-308

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication